Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | SDCBP | O00560 | 1/20 | 0.36 |
| ▸ | SDC2 | P34741 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10851353 | 0.79 | CAPN1 (0.53) | RAB9ACAPN1MMP2ANPEP | |
| SCHEMBL8498091 | 0.79 | CAPN1 (0.53) | RAB9ACAPN1MMP2ANPEP | |
| SCHEMBL3799179 | 0.78 | CAPN1 (0.41) | NPC1RAB9ACAPN1MMP2ANPEP | |
| SCHEMBL26997786 | 0.73 | DRD2 (0.46) | — | |
| SCHEMBL7990049 | 0.73 | DRD2 (0.46) | — | |
| SCHEMBL5839153 | 0.69 | LMNA (0.60) | NPC1LMNA | |
| SCHEMBL12992250 | 0.68 | CHEK1 (0.46) | MMP2ANPEP | |
| SCHEMBL13545530 | 0.68 | CHEK1 (0.46) | MMP2ANPEP | |
| SCHEMBL16266896 | 0.67 | VHL (0.56) | — | |
| SCHEMBL16266897 | 0.67 | VHL (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675859-B1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-05 | — | — | EP | disclosed |
| US-7812024-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-13 | — | — | US | disclosed |
| US-7244843-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1675859-A1 | MODULATORS OF SEROTONIN RECEPTORS | Bristol-Myers Squibb Company (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005035533-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050080074-A1 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | HTR5A, HTR1A, HTR2A | NPC1 316/4885RAB9A 1879/4885CAPN1 1970/4885 |
| US-20050080074-A1 | Modulators of serotonin receptors | HTR5A, HTR1A, HTR2B | NPC1 371/4885RAB9A 1710/4885CAPN1 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.